Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations

Journal of Pharmaceutical Sciences

Volumn 103, Issue 2, 2014, Pages 465-477

  Behara, Srinivas R B ^a,b   Longest, P Worth ^a,b   Farkas, Dale R ^a   Hindle, Michael ^b  

^a Virginia Commonwealth University   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

3D rod array; Computational fluid dynamics (CFD); Excipient enhanced growth (EEG) delivery; Flow rate effects; High efficiency DPI; In vitro inhaler testing; Multiple formulations; Non dimensional specific dissipation (NDSD); PTFE coating; Respiratory drug delivery

Indexed keywords

SALBUTAMOL SULFATE; TERBUTALINE SULFATE;

AEROSOL; ARTICLE; COMPUTATIONAL FLUID DYNAMICS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER INHALER; FLOW RATE; IN VITRO STUDY; PARTICLE SIZE; SIMULATION;

3D ROD ARRAY; COMPUTATIONAL FLUID DYNAMICS (CFD); EXCIPIENT ENHANCED GROWTH (EEG) DELIVERY; FLOW RATE EFFECTS; HIGH EFFICIENCY DPI; IN VITRO INHALER TESTING; MULTIPLE FORMULATIONS; NON-DIMENSIONAL SPECIFIC DISSIPATION (NDSD); PTFE COATING; RESPIRATORY DRUG DELIVERY;

AEROSOLS; ANALYSIS OF VARIANCE; ANTI-ASTHMATIC AGENTS; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CARRIERS; DRY POWDER INHALERS; EQUIPMENT DESIGN; EXCIPIENTS; PARTICLE SIZE; PHOTOGRAPHY; POLYTETRAFLUOROETHYLENE;

EID: 84895922767     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23775     Document Type: Article

References (49)

1. Byron PR. 2004. Drug delivery devices: Issues in drug development. Proc Am Thorac Soc 1:321-328.
2. Smith IJ, Bell J, Bowman N, Everard M, Stein S, Weers JG. 2010. Inhaler devices: What remains to be done? J Aerosol Med Pulm Drug Deliv 23:S25-S37.
3. Islam N, Cleary MJ. 2012. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery-A review for multidisciplinary researchers. Med End Phys 34:409-427.
4. Newman SP, Busse WW. 2002. Evolution of dry powder inhaler design, formulation, and performance. Respir Med 96:293-304.
5. Delvadia R, Longest PW, Byron PR. 2012. In vitro tests for aerosol deposition. I. Scaling a physical model of the upper airways to predict drug deposition variation in normal humans. J Aerosol Med 25(1):32-40.
6. Longest PW, Tian G, Walenga RL, Hindle M. 2012. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Pharm Res 29:1670-1688.
7. Zhang Y, Gilbertson K, Finlay WH. 2007. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers. J Aerosol Med 20(3):227-235.
8. Delvadia R, Hindle M, Longest PW, Byron PR. 2013. In vitro tests for aerosol deposition. II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv 26(3):138-144.
9. Borgstrom L, Olsson B, Thorsson L. 2006. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med 19:473-483.
10. Dolovich MB, Ahrens RC, Hess D. 2005. Device selection and outcomes of aerosol therapy: ACCP/ACAAI evidence based guidelines. Chest 127:335-371.
11. Smaldone GC. 2006. Advances in aerosols: Adult respiratory disease. J Aerosol Med 19(1):36-46.
12. Kamada AK, Szefler SJ, Martin RJ, Boushey HA, Chinchilli VM, Drazen JM, Fish JE, Israel E, Lazarus SC, Lemanske RF, Cherniak RM, Hurd SS, Peters SP, Sorkness C, Szefler SJ, Zwillich CW. 1996. Issues in the use of inhaled glucocorticoids. Am J Respir Crit CareMed 153(6):1739-1748.
13. Gagnadoux F, Hureaux j, Vecellio L, Urban T, Le Pape A, Valo I, Montharu J, Leblond V, Boisdron-Celle M, Lerondel S, Majoral C, Diot P, Racineux JL, Lamarie E. 2008. Aerosolized chemotherapy. J Aerosol Med 21(1):1-9.
14. Yi DD, Wiedmann TS. 2010. Inhalation adjuvant therapy for lung cancer. J Aerosol Med Pulm Drug Deliv 23(4):181-187.
15. Rubin BK. 2011. Pediatric aerosol therapy: New devices and new drugs. Respir Care 56(9):1411-1421.
16. Behara SRB, Larson I, Kippax P, Stewart P, Morton DAV. 2012. Insight into pressure drop dependent efficiencies of dry powder inhalers. Eur J Pharm Sci 46(3):142-148.
17. Prime D, Grant AC, Slater AL, Woodhouse RN. 1999. A critical comparison of the dose delivery characteristics of four alternative inhalation devices delivering salbutamol: Pressurized metered dose inhaler, Diskus inhaler, Diskhaler inhaler, and Turbuhaler inhaler. J Aerosol Med 12(2):75-84.
18. Newman SP, Pitcairn GR, Hirst PH, Bacon RE, O'Keefe E, Reiners M, Hermann R. 2000. Scintigraphic comparison of budesonide deposition from two dry powder inhalers. Eur Respir J 16(1):178-183.
19. de Boer AH, Gjaltema D, Hagedoorn P. 1996. Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: Effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers. Int J Pharm 138:45-56.
20. DeHaan WH, Finlay WH. 2004. Predicting extrathoracic deposition from dry powder inhalers. J Aerosol Sci 35:309-331.
21. Longest PW, Tian G, Li X, Son Y-J, Hindle M. 2012. Performance of combination drug and hygroscopic excipient submicrometer particles from a softmist inhaler in a characteristic model of the airways. Ann Biomed Eng 40(12):2596-2610.
22. Longest PW, Hindle M. 2012. Condensational growth of combination drug-excipient submicrometer particles: Comparison of CFD predictions with experimental results. Pharm Res 29:707-721.
23. Hindle M, Longest PW. 2012. Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: Evaluation of formulation and delivery device. J Pharm Pharmacol 64(9):1254-1263.
24. Longest PW, Hindle M. 2011. Numerical model to characterize the size increase of combination drug and hygroscopic excipient nanoparticle aerosols. Aerosol Sci Technol 45:884-899.
25. Tian G, Longest PW, Li X, Hindle M. 2013. Targeting aerosol deposition to and within the lung airways using excipient enhanced growth. J Aerosol Med Pulm Drug Deliv 26(5):248-265.
26. Son Y-J, Longest PW, Hindle M. 2013. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: Effect of spray drying process conditions on aerosol performance. Int J Pharm 443:137-145.
27. Son Y-J, Longest PW, Hindle M. 2013. Evaluation and modification of commercial dry powder inhalers for the aerosolization of submicrometer excipient enhanced growth (EEG) formulation. Eur J Pharm Sci 49:390-399.
28. Behara SRB, Farkas DR, Hindle M, Longest PW. 2013. Development of a high efficiency dry powder inhaler: Effects of a new capsule orientation and surface coatings. Pharm Res. DOI:10.1007/s11095-013-1165-6.
29. Longest PW, Son Y-J, Holbrook LT, Hindle M. 2013. Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols. Pharm Res 30:1608-1627.
30. Hindle M, Byron PR. 1995. Dose emissions from marketed dry powder inhalers. Int J Pharm 116(2):169-177.
31. USP. 2005. Physical tests and determinations: Aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers. United States Pharmacopeia First Supplement, 28-NF, General Chapter (601). Rockville, Maryland: United States Pharmacopeial Convention, pp 3298-3316.
32. Zisman WA. 1964. Relation of the equilibrium contact angle to liquid and solid constitution. In Contact angle, wettability, and adhesion; Fowkes F, Editor. Washington, DC: American Chemical Society.
33. Longest PW, Hindle M. 2009. Quantitative analysis and design of a spray aerosol inhaler. Part 1: Effects of dilution air inlets and flow paths. J Aerosol Med Pulm Drug Deliv 22(3):271-283.
34. Coates MS, Chan H-K, Fletcher DF, Raper JA. 2005. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res 22(9):1445-1453.
35. Coates MS, Chan H-K, Fletcher DF, Raper JA. 2006. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. J Pharm Sci 95(6):1382-1392.
36. Coates MS, Fletcher DF, Chan H-K, Raper JA. 2004. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: Grid structure and mouthpiece length. J Pharm Sci 93(11):2863-2876.
37. Wilcox DC. 1998. Turbulence modeling for CFD. 2nd edition. California: DCW Industries, Inc.
38. Longest PW, Hindle M. 2009. Evaluation of the respimat soft mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulm Drug Deliv 22(2):99-112.
39. Longest PW, Hindle M, Das Choudhuri S, Xi J. 2008. Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth-throat geometry. J Aerosol Sci 39:572-591.
40. Tian G, Longest PW, Su G, Walenga RL, Hindle M. 2011. Development of a stochastic individual path (SIP) model for predicting the tracheobronchial deposition of pharmaceutical aerosols: Effects of transient inhalation and sampling the airways. J Aerosol Sci 42:781-799.
41. Behara SRB, Kippax P, Larson I, Morton DAV, Stewart P. 2011. Kinetics of emitted mass-A study with three dry powder inhaler devices. Chem Eng Sci 66(21):5284-5292.2006. Emitted dose estimates from Seretide (R) Diskus (R) and Symbicort (R) Turbuhaler (R) following inhalation by severe asthmatics. Int J Pharm 316(1-2):131-137.
42. Kwok PCL, Chan HK. 2009. Electrostatics of pharmaceutical inhalation aerosols. J Pharm Pharmacol 61(12):1587-1599.
43. Byron PR, Peart J, Staniforth JN. 1997. Aerosol electrostatics I: Properties of fine powders before and after aerosolization by dry powder inhalers. Pharm Res 14(6):698-705.
44. Mazumder MK, Sims RA, Biris AS, Srirama PK, Saini D, Yurteri CU, Trigwell S, Sharma R. 2006. Twenty-first century research needs in electrostatic processes applied to industry and medicine. Chem Eng Sci 61:2192-2211.
45. Coates MS, Fletcher DF, Chan H-K, Raper JA. 2005. The role of capsule on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res 22(6):923-932.
46. Shur J, Lee SL, Adams W, Lionberger R, Tibbatts J, Price R. 2012. Effect of device design on the in vitro performance and comparability for capsule-based dry powder inhalers. AAPS J 14(4):667-676.
47. Voss AP, Finlay WH. 2002. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm 248:39-40.
48. Donovan MJ, Smyth HDC. 2010. Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations. Int J Pharm 402:1-9.
49. Hickey AJ, Concession NM, Van Oort M, Platz M. 1994. Factors influencing the dispersion of dry powders as aerosols. Pharm Tech 8:58-82.